Skip to main content

Table 2 Absolute and percentage change in eGFR in patients with CKD stages 3 and 4

From: Effect of pegloticase on renal function in patients with chronic kidney disease: a post hoc subgroup analysis of 2 randomized, placebo-controlled, phase 3 clinical trials

Parameter

PGL q2wks (n = 42)

PGL q4wks (n = 41)

Placebo (n = 20)

P value*

Absolute change in eGFR

    Mean (SD)

−2.8 (8.2)

−1.1 (11.2)

−2.7 (8.1)

0.607

    Median (min, max)

−4.12 (−19.6, 19.7)

−2.63 (−15.2, 54.6)

−2.54 (−18.6, 16.1)

 

Percent change in eGFR

    Mean (SD)

−4.2 (24.5)

−4.4 (27.3)

−5.8 (21.2)

0.853

    Median (min, max)

−10.4 (−45.5, 94.2)

−9.6 (−57.7, 106.6)

−6.1 (−46.0, 52.3)

 
  1. eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; PGL, pegloticase; q2wks, every 2 weeks; q4wks, every 4 weeks; SD, standard deviation.
  2. *A general linear model F-test, adjusted for age, sex, and race/ethnicity, was used to assess the overall impact of treatment.